258 filings
Page 4 of 13
8-K
syfvab wd
4 Jun 20
Departure of Directors or Certain Officers
5:17pm
8-K
n571aco28dkkyhu3w
11 May 20
Acceleron Reports First Quarter 2020 Operating and Financial Results
4:10pm
8-K
eniz8
5 May 20
Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
5:06pm
DEFA14A
bfl3hid7pe25o3
16 Apr 20
Additional proxy soliciting materials
4:35pm
8-K
pukdu3p740o
9 Apr 20
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
5:26pm
8-K
w2i h7bwkfhy
7 Apr 20
Departure of Directors or Certain Officers
4:39pm
8-K
xbrvajfv evoo2h
6 Apr 20
Other Events
8:41am
8-K
mv2p1veq2v
9 Mar 20
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
4:09pm
S-8
n2lcyjsu96cko6496e
27 Feb 20
Registration of securities for employees
4:22pm
8-K
93i 843ei2drfpebt0oj
27 Feb 20
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
4:10pm
8-K
uli7x7izrcla2o0w4
27 Jan 20
Other Events
4:14pm
8-K
1rwf08es
23 Jan 20
Departure of Directors or Certain Officers
4:20pm
8-K
ycbvml3
13 Dec 19
Other Events
4:35pm
8-K
x54k w6c6
9 Dec 19
Other Events
8:04am
8-K
3f8bwcrlbukiudk
6 Dec 19
Departure of Directors or Certain Officers
5:26pm
8-K
wqyrwg5zu bqr
8 Nov 19
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients
5:27pm